1235451-38-3

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Boc-5-Bromo-2-pyrimidinemethanamine is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, N-Boc-5-Bromo-2-pyrimidinemethanamine is employed as a precursor in the creation of novel agrochemicals, contributing to the advancement of crop protection and pest management solutions.
Used in Organic Compounds Synthesis:
N-Boc-5-BroMo-2-pyriMidineMethanaMine is also used as a versatile intermediate in the synthesis of a wide range of organic compounds, showcasing its importance in the field of organic chemistry for the development of new materials and chemical entities.

Upstream product

• 1193116-74-3 5-bromo-2-(bromomethyl)pyrimidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1240783-02-1 (5-bromopyrimidin-2-yl)methylamine 
• 100707-39-9 5-bromo-2-methyl-pyrimidine-4-carboxylic acid 
• 7752-78-5 5-bromo-2-methylpyrimidine 

Relevant academic research and scientific papers

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.